Abacus Wealth Partners LLC Takes Position in Gilead Sciences, Inc. $GILD

Abacus Wealth Partners LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,997 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.

A number of other large investors have also made changes to their positions in GILD. Southland Equity Partners LLC lifted its position in shares of Gilead Sciences by 2.9% during the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 92 shares in the last quarter. Argentarii LLC increased its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares during the last quarter. Peak Financial Advisors LLC grew its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 100 shares in the last quarter. Perkins Coie Trust Co grew its position in shares of Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 100 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. lifted its stake in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 0.4%

Shares of GILD opened at $114.09 on Friday. The stock has a market cap of $141.56 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 0.77 and a beta of 0.36. The company has a 50-day moving average price of $114.10 and a two-hundred day moving average price of $110.03. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,390,030 over the last ninety days. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Royal Bank Of Canada increased their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $108.00 to $127.00 in a research report on Friday, August 8th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. UBS Group raised their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Finally, Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.